OTC-QX:TRNLY

Omeq Medical Receives FDA Regulatory Clearance for its Smart Device for Epidural Injections

Retrieved on: 
Tuesday, May 9, 2023
Johns Hopkins Hospital, Marketing, Johns Hopkins, Spine, Trial of the century, SGX, Anesthesia, Patient, Physician, Epidural space, Nerve injury, LOR, FDA, Headache, Safety, Pharmaceutical industry, Medical imaging

MISGAV, Israel, May 9, 2023 /PRNewswire/ -- Omeq Medical Ltd. a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), announced today that it has received regulatory clearance from the United States Food and Drug Administration ("FDA") for its EpiFinder, which assists physicians to accurately position an epidural needle while performing the standard Loss of Resistance ("LOR") technique.

Key Points: 
  • The EpiFinder smart device offers to improve the performance of epidural technique for potentially better outcomes, with the intent to make epidural procedures safer and easier for doctors and patients."
  • Omeq Medical CEO, Lior Margalit remarked, "We are grateful to the anesthesia community that has supported our development.
  • EpiFinder is a sensor-based, battery-operated single-use epidural placement device for safe, accurate epidural injections.
  • The simple, easy-to-use device fits between a standard needle and syringe, requires no capital equipment, and is compatible with standard epidural syringes on the market.

liberDi Receives FDA Regulatory Clearance for its Digital Dialysis System

Retrieved on: 
Wednesday, January 4, 2023
Quality of life, Peritoneal dialysis, PD, Patient, Nephrology, Dialysis, Telehealth, SGX, Life expectancy, Disease, Nursing, Freedom, Innovation, FDA, Safety, Workplace, Kidney failure, Movement, Caregiver, International Society, Imperial College London, Medical device

MISGAV, Israel, Jan. 4, 2023 /PRNewswire/ -- liberDi Ltd., a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced today that it has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace, by themselves, monitored by their physician using the advanced telemedicine capabilities of the system. 

Key Points: 
  • liberDi CEO, Hezkiah Tsoory remarked, "Receiving FDA clearance for our state of the art Digital Dialysis Clinic technology, is a huge achievement for liberDi.
  • liberDi frees people from spending half of their lives in dialysis centers, which is a disruptive technology in the dialysis market."
  • liberDi conducted two initial clinical studies to demonstrate the safety and effectiveness of the Portable Peritoneal Dialysis system on patients requiring dialysis.
  • liberDi provides mobility and freedom to people on dialysis, allowing them to continue with their normal private and professional activities while on dialysis.

Collaborative Study by NeuroQuest and AIBL Shows Specific Biomarkers for Alzheimer's Could Lead to Blood-based Screening Tool

Retrieved on: 
Tuesday, November 15, 2022
Florey Institute of Neuroscience and Mental Health, Tau, Medical school, MD, Journal, Weizmann Institute of Science, MBA, CSIRO, Mental health, Research, Trial of the century, Patient, SGX, Blood, Medical University of South Carolina, Brain, Edith Cowan University, Protein, Disease, Biomarker, Medical imaging, Vaccine, Pharmaceutical industry, Dementia, Alzheimer's disease, Neuroimmunology, AB

This approach identifies disease specific immune deficits that we believe are associated with the onset of the disease.

Key Points: 
  • This approach identifies disease specific immune deficits that we believe are associated with the onset of the disease.
  • The results of the clinical study were published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association ("Alzheimer's & Dementia").
  • Newly developed disease modifying treatments for Alzheimer's disease appear to be especially effective in the early stages of clinical disease.
  • Neuroquest is an Israeli-based biotechnology company focused on the discovery of blood-based immune biomarkers in pre-clinical stage Alzheimer's.

Biotech Food Colorant Startup Phytolon Closes $14.5 Million Series A Funding Round, Led by DSM Venturing

Retrieved on: 
Thursday, July 7, 2022
Consensus, CEO, Drink, Biotechnology, Martek Biosciences Corporation, Fermentation, Vegetable, Fruit, Senior advisor, Royal, Food, DSM, Nutrition, Weizmann Institute of Science, Investment, DSM (company), Technology, SGX, Euronext Amsterdam, Animal, Solution, Board, Snack, Fine chemical, Pharmaceutical industry, Health, Enzymotec

Current natural food colors are agriculture-dependent and mostly derived from fruit and vegetables.

Key Points: 
  • Current natural food colors are agriculture-dependent and mostly derived from fruit and vegetables.
  • Dr. Halim Jubran, Co-founder and CEO of Phytolon, said: "The investments of DSM Venturing, Cibus Fund, and Ginkgo Bioworks open the door for broad penetration of our products in the global food industry.
  • We are excited to have new investors who share our vision to create healthy, efficient, and sustainable food systems via biotechnology."
  • Phytolon's Board of Directors is chaired by Steve Dubin, who played a pivotal role in directing Phytolon through this financing round.

Biotech Food Colorant Startup Phytolon Closes $14.5 Million Series A Funding Round, Led by DSM Venturing

Retrieved on: 
Thursday, July 7, 2022
Consensus, CEO, Drink, Biotechnology, Martek Biosciences Corporation, Fermentation, Vegetable, Fruit, Senior advisor, Royal, Food, DSM, Nutrition, Weizmann Institute of Science, Investment, DSM (company), Technology, SGX, Euronext Amsterdam, Animal, Solution, Board, Snack, Fine chemical, Pharmaceutical industry, Health, Enzymotec

Current natural food colors are agriculture-dependent and mostly derived from fruit and vegetables.

Key Points: 
  • Current natural food colors are agriculture-dependent and mostly derived from fruit and vegetables.
  • Dr. Halim Jubran, Co-founder and CEO of Phytolon, said: "The investments of DSM Venturing, Cibus Fund, and Ginkgo Bioworks open the door for broad penetration of our products in the global food industry.
  • We are excited to have new investors who share our vision to create healthy, efficient, and sustainable food systems via biotechnology."
  • Phytolon's Board of Directors is chaired by Steve Dubin, who played a pivotal role in directing Phytolon through this financing round.

Limaca Medical and HekaBio Announce Japan Partnership

Retrieved on: 
Monday, May 16, 2022
Population, Incidence, Patient, Adult, Medtech, FDA, Vincent Tchenguiz, Partnership, Compliance, PMDA, Biopsy, Diagnosis, Record, OTCQX, Medical device

YOKNEAM, Israel, May 16, 2022 /PRNewswire/ -- Limaca Medical ("Limaca") and HekaBio K.K. announced today that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca's Precision-GI™ Endoscopic Biopsy Device in Japan.

Key Points: 
  • YOKNEAM, Israel, May 16, 2022 /PRNewswire/ -- Limaca Medical ("Limaca") and HekaBio K.K .
  • announced today that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca's Precision-GIEndoscopic Biopsy Device in Japan.
  • This partnership has far-reaching impact for Limaca, as HekaBio provides full operational capability in Japan for Limaca's Precision-GI device and ensures compliance with Japan's PMDA regulatory requirements.
  • Limaca has an experienced team of engineers, clinicians, and business professionals with successful track records of innovating, developing, and commercializing specialized medical devices.

Limaca Medical Receives FDA Breakthrough Device Designation

Retrieved on: 
Monday, May 2, 2022
Division, Automation, Record, Breakthrough, Food, Pancreatic cancer, Patient, Trial of the century, Hepatology, Lymph, Program, Neoplasm, FDA, NYU Langone Health, Diagnosis, Blood, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD, GI, Pancreas, Liver, CEO, Vincent Tchenguiz, Precision medicine, OTCQX, Gastrointestinal tract, Biopsy, Acquisition, Medical device, Medical imaging, Gastroenterology

YOKNEAM, Israel, May 2, 2022 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision-GI™ Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • YOKNEAM, Israel, May 2, 2022 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision-GI Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA").
  • "We are pleased with the FDA's decision to grant the Breakthrough Device Designation to Precision-GI," stated Carl Rickenbaugh, Limaca's CEO.
  • The FDA Breakthrough Device Designation expedites the development and evaluation of novel devices that offer the potential to enhance patient outcomes through more effective treatment or improved diagnosis of life-threatening conditions.
  • Under the program, the FDA will provide Limaca with the opportunity to provide its feedback during the pre-market phase and prioritized review of the device submission.

Escala Medical Receives FDA Regulatory Clearance

Retrieved on: 
Wednesday, April 6, 2022
Incentive, Trial of the century, Pelvic organ prolapse, Ministry of Economic Development (Italy), Coronavirus Scientific Advisory Board (Turkey), Woman, Femtech, Health, Israel Innovation Authority, POP, Rambam Health Care Campus, Quality of life, FIH, SGX, Ministry, Prolapse, FDA, Patient, Pharmaceutical industry, Escala, Economics

MISGAV, Israel, April 6, 2022 /PRNewswire/ -- Escala Medical Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTC-QX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its first pelvic organ prolapse repair device. This clearance is concurrent with the successful completion of the one-year follow up on the first-in-human ("FIH") clinical study performed at Rambam Health Care Campus, Haifa, Israel, on 17 patients.

Key Points: 
  • joins Scientific Advisory Board
    MISGAV, Israel, April 6, 2022 /PRNewswire/ -- Escala Medical Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTC-QX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its first pelvic organ prolapse repair device.
  • Escala addresses a huge market need, offering a repair alternative that is safe and easy for the clinician to perform.
  • Escala CEO Edit Goldberg remarked, "Receiving FDA clearance for our first prolapse repair device, in addition to the recent completion of one-year follow up on our FIH clinical study, is an exciting achievement for us.
  • Dr. Robert Auerbach, Chairman of the Escala BOD added: "Escala's achievements in the emerging FemTech market makes us very proud.

Dr. Phil Davidson Named Medical Director of Arcuro Medical; Dr. Ken Zaslav Joins Arcuro Scientific Advisory Board

Retrieved on: 
Monday, March 21, 2022
Company, Clinical, Leadership, Past, Weill Cornell Medicine, Consultant, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States Air Force Scientific Advisory Board, Harvard College, Research, Orthopedic surgery, Medical director, CEO, Sports medicine, Shoulder, MD, Injury, Virginia Commonwealth University, Center, Freshwater Biological Association, Association, Hofstra University, Surgeon, Knee, SGX, SAB, Athlete, FDA, Publishing, Dentistry

MISGAV, Israel, March 21, 2022 /PRNewswire/ -- Arcuro Medical Ltd. ( www.arcuromedical.com ), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), today announced the appointment of Dr. Phil Davidson as Medical Director and Chair of the Company's Scientific Advisory Board ("SAB").

Key Points: 
  • MISGAV, Israel, March 21, 2022 /PRNewswire/ -- Arcuro Medical Ltd. ( www.arcuromedical.com ), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), today announced the appointment of Dr. Phil Davidson as Medical Director and Chair of the Company's Scientific Advisory Board ("SAB").
  • Dr. Ken Zaslav joins Dr. Davidson as a founding member of the SAB.
  • The founding members of the Arcuro SAB are Dr. Phil Davidson and Dr. Ken Zaslav.
  • Dr. Davidson graduated from Harvard College and received his MD degree with Honors in Research from Cornell University Medical College.

Phytolon and Ginkgo Bioworks Collaborate to Take Biological Production of Vibrant Food Colors to the Next Level

Retrieved on: 
Monday, February 28, 2022
Consensus, Commercial, Risk, U.S. Securities and Exchange Commission, Therapy, Partnership, SGX, Efficiency, CTO, Cell engineering, Computer, Biotechnology, K-12, COVID-19, Industry, Fermentation, Biology, Food industry, NYSE, DNA, Soarin' Eagle, Food, Forward-looking statement, Synthetic biology, Ginkgo Bioworks, Technology, Agriculture, Solution, Program, SEC, Cochineal, Fine chemical, Ginkgo

YOKNEAM ILLIT, Israel, Feb. 28, 2022 /PRNewswire/ -- Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to take Phytolon's colors across the full 'yellow-to-purple' spectrum to the next level, and to potentially maximize the business opportunity of Phytolon's vibrant colors for applications in the food and cosmetics industries.

Key Points: 
  • The project aims to take Phytolon's colors across the full 'yellow-to-purple' spectrum to the next level, and to potentially maximize the business opportunity of Phytolon's vibrant colors for applications in the food and cosmetics industries.
  • Biotechnology offers an opportunity to tap into the vibrant colors of biology to produce more sustainable, yet equally vibrant, colors.
  • While artificial dyes are visually appealing and cheap to manufacture, many have been banned in food and feed due to health concerns.
  • Together, Phytolon and Ginkgo are partnering with the goal of maximizing the production efficiency of purple and yellow betalain-producing strains.